BioStock: Prolight Diagnostics selects partner to conduct clinical validation studies

Prolight Diagnostics has appointed MDx CRO to perform clinical validation studies with the company's digital point-of-care analysis system, Psyros, for high sensitivity troponin testing. The clinical validation is planned to start in early 2025 and is expected to form the basis for IVDR approval and commerical launch.
– With MDx, we have gained an extremely experienced and responsive partner with deep sector knowledge and high expertise, says CEO Ulf Bladin.

Read the article at biostock.se:

Prolight Diagnostics selects partner to conduct clinical validation studies - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/